BR9912198A - Nova forma do irbesartan, processos para se obter essa forma e composições farmacêuticas que o contém - Google Patents

Nova forma do irbesartan, processos para se obter essa forma e composições farmacêuticas que o contém

Info

Publication number
BR9912198A
BR9912198A BR9912198-0A BR9912198A BR9912198A BR 9912198 A BR9912198 A BR 9912198A BR 9912198 A BR9912198 A BR 9912198A BR 9912198 A BR9912198 A BR 9912198A
Authority
BR
Brazil
Prior art keywords
irbesartan
crystalline
processes
pharmaceutical compositions
obtaining
Prior art date
Application number
BR9912198-0A
Other languages
English (en)
Inventor
Bruno Franc
Christian Hoff
San Kiang
Mark D Lindrud
Chenkou Wei
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9912198(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR9912198A publication Critical patent/BR9912198A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"NOVA FORMA DO IRBESARTAN, PROCESSOS PARA SE OBTER ESSA FORMA E COMPOSIçõES FARMACêUTICAS QUE O CONTéM"<D>. Irbesartan forma A tendo um aspecto cristalino modificado, de modo que a relação entre o comprimento e a largura dos cristais esteja compreendida entre 1:1 e 10:1, preferencialmente entre 1:1 e 5:1 e um processo para o preparo desse aspecto cristalino, caracterizado pelo fato de ou se submeter uma suspensão cristalina de irbesartan forma A com aspecto de agulha a pelo menos um episódio de oscilação de temperatura, ou se submeter uma suspensão cristalina de irbesartan forma com aspecto de agulha a um cisalhamento mecânico. Composição farmacêutica contendo esse aspecto cristalino do irbesartan.
BR9912198-0A 1998-06-24 1999-06-10 Nova forma do irbesartan, processos para se obter essa forma e composições farmacêuticas que o contém BR9912198A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PCT/FR1999/001372 WO1999067236A1 (fr) 1998-06-24 1999-06-10 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
BR9912198A true BR9912198A (pt) 2001-04-10

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912198-0A BR9912198A (pt) 1998-06-24 1999-06-10 Nova forma do irbesartan, processos para se obter essa forma e composições farmacêuticas que o contém

Country Status (25)

Country Link
US (2) US6800761B1 (pt)
EP (1) EP1089994B9 (pt)
JP (1) JP2002518495A (pt)
KR (1) KR20010034917A (pt)
CN (1) CN1127499C (pt)
AT (1) ATE275562T1 (pt)
AU (1) AU747887B2 (pt)
BG (1) BG105069A (pt)
BR (1) BR9912198A (pt)
CA (1) CA2335545A1 (pt)
CZ (1) CZ292868B6 (pt)
DE (1) DE69920017T2 (pt)
EA (1) EA003410B1 (pt)
FR (1) FR2780403B3 (pt)
HU (1) HUP0103913A3 (pt)
ID (1) ID27377A (pt)
IL (1) IL140419A0 (pt)
NO (1) NO317786B1 (pt)
NZ (1) NZ508842A (pt)
PL (1) PL345215A1 (pt)
SK (1) SK20032000A3 (pt)
TR (1) TR200003842T2 (pt)
UA (1) UA55540C2 (pt)
WO (1) WO1999067236A1 (pt)
ZA (1) ZA200007588B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
CN101165062A (zh) * 2003-01-16 2008-04-23 特瓦制药工业有限公司 伊贝沙坦的新合成方法
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
DE602004015071D1 (de) * 2003-02-05 2008-08-28 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4-on
KR20060119893A (ko) * 2003-08-27 2006-11-24 베링거 인겔하임 인터내셔날 게엠베하 사이클로알킬아미노산 화합물, 이를 제조하는 방법 및 이의용도
WO2005113518A1 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Process for preparing irbesartan
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
TWI346108B (en) 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20090208573A1 (en) * 2004-11-11 2009-08-20 Lek Pharmaceuticals D.D Novel polymorph form of irbesartan
EP1806130B1 (en) 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2008125388A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
CN101801371B (zh) * 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
EP2065035B1 (en) * 2007-11-28 2010-07-21 Laboratorios Lesvi, S.L. Pharmaceutical formulations containing irbesartan
US20100234614A1 (en) * 2007-12-07 2010-09-16 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
SI2451797T1 (sl) * 2009-07-10 2013-07-31 Janssen Pharmaceutica, N.V. Postopek kristalizacije 1-(beta-d-glukopiranosil)-4-metil-3-(5-(4-fluorofenil)-2-tienilmetil) benzena
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
BR112012008939B1 (pt) * 2009-10-14 2021-06-22 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt2
EA022365B1 (ru) 2010-05-11 2015-12-30 Янссен Фармацевтика Нв Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
DK3394051T3 (da) * 2015-12-21 2020-07-20 Janssen Pharmaceutica Nv Krystallisationsprocedure til opnåelse af krystaller af canagliflozinhemihydrat

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
TR200003842T2 (tr) 2001-06-21
CA2335545A1 (en) 1999-12-29
HUP0103913A3 (en) 2003-01-28
NZ508842A (en) 2002-09-27
US6800761B1 (en) 2004-10-05
CZ20004771A3 (en) 2001-06-13
DE69920017D1 (de) 2004-10-14
FR2780403A1 (fr) 1999-12-31
UA55540C2 (uk) 2003-04-15
CZ292868B6 (cs) 2003-12-17
EP1089994B1 (fr) 2004-09-08
IL140419A0 (en) 2002-02-10
US7008959B2 (en) 2006-03-07
EA003410B1 (ru) 2003-04-24
EA200001221A1 (ru) 2001-08-27
EP1089994A1 (fr) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
BG105069A (en) 2001-11-30
WO1999067236A1 (fr) 1999-12-29
DE69920017T2 (de) 2005-09-22
AU4048499A (en) 2000-01-10
EP1089994B9 (fr) 2008-08-27
NO20006645D0 (no) 2000-12-22
CN1306529A (zh) 2001-08-01
NO317786B1 (no) 2004-12-13
CN1127499C (zh) 2003-11-12
FR2780403B3 (fr) 2000-07-21
JP2002518495A (ja) 2002-06-25
NO20006645L (no) 2001-02-26
KR20010034917A (ko) 2001-04-25
AU747887B2 (en) 2002-05-30
PL345215A1 (en) 2001-12-03
ATE275562T1 (de) 2004-09-15
US20050032862A1 (en) 2005-02-10
ZA200007588B (en) 2001-06-11
SK20032000A3 (sk) 2001-05-10
ID27377A (id) 2001-04-05

Similar Documents

Publication Publication Date Title
BR9912198A (pt) Nova forma do irbesartan, processos para se obter essa forma e composições farmacêuticas que o contém
BR0011481A (pt) Processo para produzir um óleo base aperfeiçoado, e, estoque de base de óleo lubrificante
BR8802474A (pt) Composicao capaz de aperfeicoar pelo menos and propriedade de escoamento em baixa temperatura de uma composicao de oleo lubrificante,concentrado de oleo lubrificante e processo para aperfeicoamento de pelo menos as propriedades de escoamento em baixa temperatura de uma composicao de oleo lubrificante
BR8803120A (pt) Processo para obtencao de material fundido de amido desestruturado e processo para obtencao de amido
DE69429441D1 (de) Tricyclische amide und harnstoffderivate zur inhibierung der g-protein funktion und für die behandlung von proliferatinen erkrankungen
BR9907895A (pt) Processo para preparar uma composição denanocompósito polimérica
BR9913491A (pt) Composições biodegradáveis à base de amido e ésteres de polissacarìdeos e processo para aumentar sua biodegradabilidade
BR9809132A (pt) Composição escoável e um processo para produção da composição escoável
BR9912226A (pt) Aço de carbonetação à temperatura de revenido elevada, processo para a sua obtenção e peças de aço resultantes
BR9508294A (pt) Composto de triazol processo para a preparação dos mesmos composição farmacêutica e utilização de pelo menos um composto
EA200100533A1 (ru) Производные эритромицина, способ их получения и их применение в качестве лекарственных средств
BR9908608A (pt) Poliamida estável à luz e ao calor, processo para produção da mesma, e, artigo
BR9801736A (pt) Processo de produção de dextrano.
CO4970688A1 (es) Procedimientos para purificar mesilato de alatrofloxacino
ES2073793T3 (es) 2-octiniladenosina estable solida y procedimiento para su preparacion.
BR9001734A (pt) Composto inseticida de diamino-etileno,processo para sua preparacao e composicao inseticida que o contem
BR9302029A (pt) Metodo para produzir uma composicao,metodo para produzir uma solucao aquosa,composicao,e,processo para retardar o crescimento microbial
PT92180A (pt) Processo para a preparacao de novas mevalonolactonas do tipo tienopiridina e de composicoes farmaceuticas que as contem
BR9913010A (pt) Composto, composição farmacêutica, e, processo para o tratamento de distúrbios responsivos à abertura dos canais de potássico ativado por cálcio de grande condutância em um mamìfero em sua necessidade.
ES2152418T3 (es) Modificacion del aceite.
BR8604698A (pt) Processo para a preparacao de compostos,processo para a preparacao de uma composicao,processo para combater ou proteger uma infestacao de plantas,composicoes praguicidas
PT95651A (pt) Processo para a preparacao de derivados de benzo-ciclo-alquilamino-piridinaminas e de composicoes farmaceuticas que os contem
BR0114404A (pt) Processo para produzir tira de aço e tira de aço fundida produzida pelo mesmo
BR9408195A (pt) Conjugados de hirudina formados de uma hirudina e um ou vários compostos lipófilos e processo para a produção de conjugados de hirudina
PT94760A (pt) Processo para a preparacao de uma tiona e de uma composicao biocida que a contem

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008.